blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3164156

EP3164156 - STABILISED FORMULATIONS OF RNA [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  06.03.2020
Database last updated on 12.11.2024
FormerRequest for examination was made
Status updated on  07.04.2017
FormerThe international publication has been made
Status updated on  31.01.2017
Most recent event   Tooltip24.07.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
BioNTech AG
An der Goldgrube 12
55131 Mainz / DE
[2017/19]
Inventor(s)01 / PASCOLO, Steve
Kanzleistr. 231
8004 Zürich / CH
 [2017/19]
Representative(s)Schnappauf, Georg
ZSP Patentanwälte PartG mbB
Hansastraße 32
80686 München / DE
[N/P]
Former [2017/19]Schnappauf, Georg
ZSP Patentanwälte PartG mbB
Radlkoferstrasse 2
81373 München / DE
Application number, filing date14736770.004.07.2014
[2017/19]
WO2014EP64335
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016000792
Date:07.01.2016
Language:EN
[2016/01]
Type: A1 Application with search report 
No.:EP3164156
Date:10.05.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 07.01.2016 takes the place of the publication of the European patent application.
[2017/19]
Search report(s)International search report - published on:EP07.01.2016
ClassificationIPC:A61K47/50, A61K47/26
[2017/19]
CPC:
A61K47/26 (EP,US); C12N15/117 (US); A61K39/39 (US);
A61K47/6455 (EP,US); A61K47/6931 (EP,US); A61K48/0041 (US);
A61K9/0019 (EP,US); A61K2039/55561 (US); C12N2310/17 (US);
C12N2310/351 (US); C12N2320/32 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/19]
Extension statesBA30.01.2017
ME30.01.2017
TitleGerman:STABILISIERTE FORMULIERUNGEN VON RNA[2017/19]
English:STABILISED FORMULATIONS OF RNA[2017/19]
French:PRÉPARATIONS D'ARN STABILISÉES[2017/19]
Entry into regional phase30.01.2017National basic fee paid 
30.01.2017Designation fee(s) paid 
30.01.2017Examination fee paid 
Examination procedure30.01.2017Examination requested  [2017/19]
30.01.2017Date on which the examining division has become responsible
17.07.2017Amendment by applicant (claims and/or description)
10.03.2020Despatch of a communication from the examining division (Time limit: M04)
27.05.2020Reply to a communication from the examining division
27.11.2020Despatch of a communication from the examining division (Time limit: M04)
16.02.2021Reply to a communication from the examining division
15.01.2024Despatch of a communication from the examining division (Time limit: M04)
15.05.2024Reply to a communication from the examining division
Fees paidRenewal fee
30.01.2017Renewal fee patent year 03
26.07.2017Renewal fee patent year 04
31.07.2018Renewal fee patent year 05
31.07.2019Renewal fee patent year 06
13.07.2020Renewal fee patent year 07
12.07.2021Renewal fee patent year 08
11.07.2022Renewal fee patent year 09
20.07.2023Renewal fee patent year 10
23.07.2024Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]WO03106636  (MIRUS CORP [US]) [X] 1-28 * examples 83-84 *;
 [X]WO2004028560  (POWDERJECT RES LTD [GB], et al) [X] 1-28 * page 31; table 1 *;
 [X]WO2008054544  (CBR INST FOR BIOMED RES INC [US], et al) [X] 1-28 * example 3 *;
 [X]US2009042829  (MATAR MAJED [US], et al) [X] 1-28 * example 7 *;
 [X]WO2009036368  (NITTO DENKO CORP [JP], et al) [X] 1-28 * examples 9,11 *;
 [X]WO2009144481  (ISIS INNOVATION [GB], et al) [X] 1-28 * example 3 *;
 [X]WO2011069529  (CUREVAC GMBH [DE], et al) [X] 1-28 * example 5 *;
 [E]WO2014133351  (CHONG KUN DANG PHARM CORP [KR]) [E] 1-28 * page 17 - page 18; examples 23-24; table 4 ** page 24; example 6 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.